Campbell & CO Investment Adviser LLC Buys Shares of 74,549 BioMarin Pharmaceutical Inc. $BMRN

Campbell & CO Investment Adviser LLC purchased a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 74,549 shares of the biotechnology company's stock, valued at approximately $4,098,000.

• Can BioMarin Stock Live Up to Wall Street’s High Expectations?

Other large investors have also recently bought and sold shares of the company. Nuveen LLC bought a new position in BioMarin Pharmaceutical during the first quarter valued at about $184,475,000. AQR Capital Management LLC raised its stake in shares of BioMarin Pharmaceutical by 127.9% in the 1st quarter. AQR Capital Management LLC now owns 2,925,805 shares of the biotechnology company's stock valued at $203,987,000 after acquiring an additional 1,642,206 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of BioMarin Pharmaceutical by 212.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company's stock valued at $112,607,000 after acquiring an additional 1,083,512 shares in the last quarter. Fuller & Thaler Asset Management Inc. acquired a new stake in BioMarin Pharmaceutical in the 1st quarter worth approximately $59,125,000. Finally, Robeco Institutional Asset Management B.V. boosted its position in BioMarin Pharmaceutical by 559.8% during the second quarter. Robeco Institutional Asset Management B.V. now owns 641,718 shares of the biotechnology company's stock worth $35,275,000 after purchasing an additional 544,457 shares during the period. 98.71% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BMRN. JPMorgan Chase & Co. lifted their price target on shares of BioMarin Pharmaceutical from $116.00 to $119.00 and gave the company an "overweight" rating in a research report on Thursday, October 9th. Tudor Pickering set a $88.00 target price on shares of BioMarin Pharmaceutical in a report on Monday, November 3rd. Zacks Research cut shares of BioMarin Pharmaceutical from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. Stifel Nicolaus reaffirmed a "hold" rating and issued a $61.00 price target (down from $73.00) on shares of BioMarin Pharmaceutical in a research report on Thursday. Finally, Morgan Stanley cut their price objective on BioMarin Pharmaceutical from $104.00 to $98.00 and set an "overweight" rating for the company in a research report on Tuesday, October 28th. Sixteen research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $89.91.

• 3 Oversold Stocks with Big RSI Rebound Potential

Get Our Latest Report on BMRN

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $51.46 on Friday. The firm's 50-day moving average is $54.19 and its 200-day moving average is $56.82. The company has a market cap of $9.89 billion, a price-to-earnings ratio of 19.35, a PEG ratio of 0.68 and a beta of 0.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.60 and a current ratio of 4.83. BioMarin Pharmaceutical Inc. has a 52-week low of $50.76 and a 52-week high of $73.51.

BioMarin Pharmaceutical Company Profile

• Are Gene Therapy Stocks The Market's Next Big Winners?

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Articles

• Five stocks we like better than BioMarin Pharmaceutical
• High Flyers: 3 Natural Gas Stocks for March 2022
• Rivian’s Chart Says Go, But Some Analysts Still Say No
• The Basics of Support and Resistance
• e.l.f. Sell-Off Is a Good Time to Buy, According to Analysts
• What is a support level?
• T-Mobile Is The Most Oversold Mega-Cap Stock—Time to Buy?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in BioMarin Pharmaceutical Right Now?

Before you consider BioMarin Pharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.

While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here